Bibliography
- Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-85
- Binder V, Hendriksen C, Kreiner S. The long-term prognosis in ulcerative colitis. Results from a regional patient group in the county of Copenhagen. Gut 1985;26(2):146-50
- Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003;98(5):1064-72
- Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992;14(4):309-17
- Everhart JE. editor. The burden of digestive diseases in the United States. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Government Printing Office; Washington, DC: 2008. NIH Publication No. 09-6443
- Uzunov P, Weiss B. Separation of multiple molecular forms of cyclic adenosine 3',5'-monophosphate phosphodiesterase in rat cerebellum by polyacrylamide gel electrophoresis. Biochim. Biophys. Acta 284:220-6.1972
- Strada SJ, Uzunov P, Weiss B. Ontogenetic development of a phosphodiesterase activator and the multiple forms of cyclic AMP phosphodiesterase of rat brain. J Neurochem 1974;23:1097-103
- Weiss B, Hait WN. Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents. Ann Rev Pharmacol Toxicol 1977;17:441-77
- Salari-Sharif P, Abdollahi M. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review. Curr Pharm Des 2010;16:3661-7
- Ichikawa H, Okamoto S, Kamada N, Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. Inflamm Bowel Dis 2008;14:1483-90
- Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 2004;25:430-6
- Keshavarzian A, Mutlu E, Guzman JP, Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs 2007;16(9):1489-506
- Schreiber S, Keshavarzian A, Isaacs KL, A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 2007;132:76-86
- O'Mahony S. Tetomilast. IDrugs 2005;8(6):502-7
- Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Inves Drugs 2007;8(5):364-72
- Mallikaarjun S, Shoaf S, Zhang P, Pharmacokinetics (PK) and pharmacodynamics (PD) of tetomilast in stable COPD subjects [Poster 3838]. Presented at the European Respiratory Society Annual Meeting; 5 September 2006
- Lauritsen K, Laursen LS, Bukhave K, Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986;91(4):837-44
- Hillingsø J, Kjeldsen J, Laursen LS, Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis. Clin Pharmacol Ther 1995;57(3):335-41
- Roberts WG, Simon TJ, Berlin RG, Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997;112(3):725-32
- Jupp J, Hillier K, Elliott DH, Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13(5):537-46
- Narushima S, DiMeo D, Tian J, 5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice. Am J Physiol Gastrointest Liver Physiol 2008;294(2):G477-88
- Targan SR, Feagan BG, Fedorak RN, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132(5):1672-83